Optimizing the design of the clinical trials of the futureBoosting power for clinical trials using classifiers based on multiple biomarkers
Section snippets
Subjects
Baseline neuroimaging and biomarker data were downloaded from the ADNI public database (www.loni.ucla.edu/ADNI/Data/) on or before 20 November 2009 and reflect the status of the database at that point; as data collection is ongoing. ADNI is a large 5 year study launched in 2004 with the primary goal of testing whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessments at multiple sites (as in a typical clinical trial), can replicate results from smaller
AD and MCI classification based on MRI markers, ApoE genotype and demographic information
We first used the three MRI-derived summaries, ApoE genotype and demographic variables (age, sex and BMI) for AD and MCI classification with 635 ADNI subjects. SVM training was performed with all seven features using a linear kernel with C = 1, and the contributions of the different biomarkers were put into a rank order (best to worst) based on their SVM weights, assessed by wi2 in the notation of SVM described in the methods. The rank orders are shown in Table 2.
We then aimed to find the top N
Discussion
We explored the power of several baseline biomarkers for AD and MCI, used jointly for diagnostic classification and for predicting future (1 year) cognitive decline in MCI. We also showed how to apply the multimodality classifiers to choose subsamples of subjects for boosting power in clinical trials. We determined combinations of regional MRI numerical summaries with demographic variables and ApoE that best classified AD vs. control and MCI vs. control. The top set of complementary biomarkers
Disclosure statement
The authors have no potential financial or personal conflicts of interest including relationships with other people or organizations within 3 years of beginning the work submitted that could inappropriately influence their work.
Acknowledgements
Data collection and sharing for this project was funded by the Alzheimer's disease Neuroimaging Initiative (ADNI) (National Institutes of Health, Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare,
References (71)
- et al.
Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment Assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative
Neuroimage 51
(2010) - et al.
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls
Neuroimage
(2009) - et al.
Mapping genetic influences on ventricular structure in twins
Neuroimage
(2009) - et al.
Automated ventricular mapping with multi-atlas fluid image alignment reveals genetic effects in Alzheimer's disease
Neuroimage
(2008) - et al.
Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI
Neuroimage
(2008) - et al.
Investigating the predictive value of whole-brain structural MR scans in autism: A pattern classification approach
Neuroimage
(2010) - et al.
Structural and functional biomarkers of prodromal Alzheimer's disease: a high-dimensional pattern classification study
Neuroimage
(2008) - et al.
Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers
J Nutr Health Aging
(2009) - et al.
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset
Neuroimage
(2009) - et al.
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals
Neuroimage
(2010)
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects
Neuroimage
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry
Neuroimage
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects
Neuroimage
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Lancet Neurol
Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort
Neuroimage
Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls
Neurobiol Aging
Brain tumor classification based on long echo proton MRS signals
Artif Intell Med
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls
Neuroimage
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls
Neuroimage
Classifying brain states and determining the discriminating activation patterns: Support Vector Machine on functional MRI data
Neuroimage
Alzheimer's disease: progress in prediction
Lancet Neurol
FDDNP binding using MR derived cortical surface maps
Neuroimage
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease
Neuroimage
Elucidating an MRI-based biomarker for psychosis: classification using probabilistic brain atlas and machine learning algorithms
Biol Psychiatry 66
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies
Neuroimage
Automated MRI-based classification of primary progressive aphasia variants
Neuroimage
Use of the Support Vector Machine and Sensitivity of an AD-Related Region-of-Interest Gray Matter Classifier in Identifying Amnestic MCI Subjects Who Convert t6o AD: Preliminary Findings From the AD Neuroimaging Initiative
Presented at the International Conference on Alzheimer's Disease, Chicago, July 26–
Six month MRI gray matter declines in Alzheimer's dementia evaluated by voxel-based morphometry with multivariate network analysis: Preliminary findings from the Alzheimer's Disease Neuroimaging Initiative
Alzheimers Dement
Alzheimer's disease facts and figures
Alzheimers Dement
3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
Brain
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps
Arch Neurol
Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
Arch Neurol
Gender differences in dementia risk factors
Gend Med
Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease
Neurobiol Aging Nov 10
Change in body mass index and risk of incident Alzheimer disease
Neurology
Cited by (0)
- †
Data used in the preparation of this article were obtained from the Alzheimer's disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu/ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. Complete listing of ADNI investigators available at: www.loni.ucla.edu/ADNI/Collaboration/ADNI_Manuscript_Citations.pdf.